

Exendin-4

Catalog # PVGS1114

Product Information

Primary Accession Species	P26349 Gila monster
Sequence	His48-Ser86
Purity	> 96% as analyzed by SDS-PAGE > 96% as analyzed by HPLC
Endotoxin Level	
Expression System	E. coli
Theoretical Molecular Weight	4.2 kDa
Formulation	Lyophilized from a 0.2 μ m filtered solution in PBS, pH 7.4.
Reconstitution	It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0 mg/ml.
Storage & Stability	Upon receiving, this product remains stable for up to 6 months at -70°C or -20°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. Avoid repeated freeze-thaw cycles.

Additional Information

Other Names	Exendin-4, Exenatide, EXE4
Target Background	Exendin-4 is a novel 39-amino acid peptide isolated from the venom of the Gila monster <i>Heloderma suspectum</i> . It shares 53% sequence homology with GLP-17-36amide and interacts with the same membrane receptor. Exendin-4 enhances glucose-dependent insulin secretion, suppresses inappropriately elevated glucagon secretion, and slows gastric emptying in vivo. It also promotes β -cell proliferation and neogenesis in vitro and in animal models.

Protein Information

Name	EXE4
Function	Venom protein that mimics the incretin hormone glucagon-like peptide 1 (GLP-1). It stimulates insulin synthesis and secretion, protects against beta-cell apoptosis in response to different insults, and promotes beta-cell proliferation. It also promotes satiety, reduces food intake, reduces fat

deposition, reduces body weight and inhibits gastric emptying. Interacts with GLP-1 receptor (GLP1R). Induces hypotension that is mediated by relaxation of cardiac smooth muscle.

Cellular Location

Secreted.

Tissue Location

Expressed by the venom gland.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.